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Cross border reproductive care - the EUTCD perspective 
 
We live in a world with no medical borders. An ever-increasing number of 
patients with infertility or desiring a family through ART, in the circumstances of 
physiological impossibility of conceiving or carrying a pregnancy, are seeking 
treatment outside their country of residence. Furthermore, couples that want to avoid 
the transmission of an inheritable condition to their offspring are willing to travel to 
countries where techniques like Pre-Implantation Genetic Diagnosis (PGD) are 
practiced.  
The European Society for Human Reproduction and Embryology (ESHRE) has 
studied this phenomenon of Cross Border Reproductive Care (CBRC) and established 
a ESHRE CBRC Task Force which proposed guidelines on the delivery of care in the 
circumstances of CRBC.  
The present paper will look at the challenges of implementing the European 
Directives in the circumstances of CBRC.  I will specifically deal with a short 
summary of the legal requirements, limited data on CBRC and relevant challenges for 
the parties involved, namely the patients, the country of residence and the “child to 
be”. 
The legal requirements 
The quality and safety of reproductive laboratory activity has been addressed 
by the EU Directives 2004/23/EC, 2006/ 17/EC and 2006/86/EC as early as 10 years 
ago1,2,3. The transposition into law, in each European country, ensures that individual 
patient interests and public health are safeguarded at pan-European level. 
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The 2004/23/EC (Mother) Directive deals with standards of quality and safety 
for the donation, procurement, testing, processing, preservation, storage and 
distribution of human tissues and cells, as pertinent to the field of Assisted 
Reproduction. The 2006/ 17/EC (Technical 1) Directive addresses the technical 
requirements for the donation, procurement and testing of human tissues and cells 
while the 2006/86/EC (Technical 2) Directive details traceability requirements, 
notification of serious adverse reaction/ events and certain technical requirements for 
the coding, processing, preservation, storage and distribution of human tissues and 
cells. 
Each European country was requested to transpose the Directive into national 
law and establish a national Competent Authority (CA) to supervise the 
implementation of such national laws.  Among the duties of the CA is the requirement 
to inspect and license all ART laboratories in the country.  Specifically, all Assisted 
Reproductive Technology (ART) units must be authorized, accredited and have 
efficient quality systems run by a Quality Manager. 
From a clinical perspective the requirements refer to: 
a. risk reduction (serology testing of all patients embarking on ART where 
processing of a reproductive sample, i.e. sperm, oocytes, embryos, including 
frozen tissues and cell, is to take place; evidence of certified training and 
training re-validation on regular basis); 
b. identification of risk (compulsory serious adverse events and reactions 
(SARE) reporting) and long-term follow-up (confidentiality and data storage 
for 30 years).  
At laboratory level clear stipulations cover: 
a. processing (air quality, microbial and particle monitoring),  
b. storage of reproductive material (continuously monitored, infectious risk 
segregated),  
c. traceability (from donor to recipient),  
d. coding (unique identifier code for all reproductive material that is exported to 
another country) and  
e. compulsory reporting of SARE in the laboratory sphere. 
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Cross Border Reproductive Care (CRBC) 
CRBC or the process of obtaining or providing reproductive treatment outside 
patient’s home country has been extensively studied previously4. There is a double 
flow across European and world borders at present (Figure 1). 
Figure 1. Cross-border movement of patients and reproductive material. 
 
 
It is crucial to acknowledge that both patients and reproductive material 
regularly transit inter-country borders. Only the later are monitored and regulated part 
of the implementation of EUTC national laws and under the supervision of national 
Competent Authorities. 
Research data from Europe4 suggest that 6% (1 in 16) ART treatments in 
Europe are performed outside the country of residence. The authors quote up to 
30,000 cycles yearly, performed for up to 20,000 patients. In the US, the Centre for 
Disease Control reported and incidence of 4% (6,000 cycles) in 20085. 
Areas of risk during CBRC 
During the provision of medical care for couples seeking ART therapy each 
step of the process carries risks (Table 1). 
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Table 1. Areas of risk in CRBC. 
 
 
Selection 
The patient selection process involves responsibility in selecting right donors, 
free of genetic diseases like cystic fibrosis (CF) or infectious conditions like Hepatitis 
or HIV that can be transmitted to the recipient or the offspring (CF). Similarly, 
practitioners should ensure that patients themselves are suitable for therapy and 
pregnancy. For example, in women with Turner Syndrome (45,XO), co-arctation of 
the aorta, a congenital malformation well described in this group exposes both the 
pregnant woman and her baby to a major risk (50% likelihood), namely maternal 
death during pregnancy. Practitioners have a duty to inform all such patients, prior to 
egg donation, of the risks ahead and even advise them against a pregnancy in the 
circumstances of above evidence. 
Processing 
The processing of sperm and eggs in the ART laboratory falls under the 
European Directives. Even with the best quality systems in place errors during the 
fertilization, incubation (storage), assessment and release of gametes or embryos can 
occur.  Some of the errors can have significant implications. 
Infection occurring in the culture dish (from one of the partners) as the semen 
is not a guaranteed sterile environment, neither is the vagina. Vaginal bacteria can 
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contaminate the oocyte collection needle and such infection can be evident in the 
culture media after extensive culture. Any alteration in culture media parameters due 
to either faulty production or transport and storage can have a dramatic impact upon 
the development of embryos in vitro, in worse scenarios resulting in total loss of 
embryos. 
Misdiagnosis of normality in an affected embryo after pre-implantation 
genetic diagnosis (PGD) is particularly unfortunate as couples avail of such services 
in order to specifically find an unaffected embryo. Usually, this is not related to the 
test performance but to the erroneous allocation of a result to a specific embryo. 
Distribution 
The release of embryos for transfer can result in undesired complications for 
the patients.  
Mix–up of gametes or embryos is a well-described complication of ART. For 
couples embarking in CBRC is has devastating consequences, particularly as many 
have attended for specific purpose (donor eggs, sperm or embryos; PGD). Loss of 
embryos at time of transfer is a theoretical occurrence.  Culture dish dropping with the 
consequent loss of embryos can occur in practice yet, no cases have been published to 
date. 
Storage 
Tank failure is a recognized clinical occurrence and unless full remote 
monitoring is in place will result in total loss of reproductive material. Cross-infection 
can occur in the circumstances of poor sealement of storage vessels and use of non-
high security straws for cryopreservation. Sample segregation (separate storage for 
couples where a partner is seropositive) and the use of high security straws should 
eliminate this risk.  
Reproductive material samples can be lost as consequence of storage vessel 
breakage when the material is release in the liquid or vapour nitrogen environment. 
Appropriate training, handling of stored canes only when required and following 
procedures carefully reduce such risks to a minimum. 
Clinical 
Severe reaction to recommended medication used is rare but potentially 
severely damaging. Of interest is the use of medication with scientifically unproven 
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benefits which could potentially expose patients to unnecessary risks (steroid or 
anticoagulant use). Any oocyte collection surgical procedure exposes females to the 
risks of injury to pelvic organs like bowel or blood vessels, which may present days 
after the oocyte collection operation performed abroad. Ovarian hyperstimulation 
syndrome, a potentially lethal complication of ovarian stimulation occurs in 1% of all 
treatments. The patient attending for ART abroad could present as late as 7-9 days 
afterwards to the services in the country of residence.  Severe dehydration, vomiting, 
renal and respiratory failure with death are well described in the literature. 
Management is ambulatory in mild cases and requiring admission with intensive care 
is severe. From a stimulation and procurement perspective not all clinics follow up 
their patients after treatment or after a pregnancy establishes. It is notoriously difficult 
to obtain post treatment data. As such events like OHSS will not be always known to 
the treating IVF centre and thus not reported.  
Such serious adverse events and reactions occurring during or after treatments 
abroad require compulsory reporting to national CA as specified by the 
recommendations made in the SOHO V&S EU Project 6 (Figure 2).  
 
Figure 2. Recommendations on occurrence of SARE in CRBC. 
 
CA’s should encourage health professionals to report SARE even when it is established 
to be related to ART CBRC. 
 
In the case of CRBC, the CA receiving the SARE notification should inform the other 
CA’s concerned without any delay. 
 
CA’s should encourage Tissue Establishments (TE’s) to promote information about any 
adverse outcomes. 
 
 
 
Furthermore, the Guidance on Vigilance provides all units and practitioners 
with examples of risks and risk assessment tools to be used in practice. 
Nevertheless, the implementation of ART vigilance raises some very specific 
challenges in that practitioners and clinics that report could become a target for the 
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press and suffer loss of business despite doing the “right thing”. The issue is not what 
to report but how to encourage clinics to report SARE while maintaining patient 
confidence and not creating unnecessary anxiety among patients? 
 
The couples 
The main services accessed by couples seeking ART abroad are donor 
gametes or embryos, surrogacy, PGD, gender selection and cheaper IVF/ ICSI 
treatments. While English is spoken widely it is envisaged that language barriers will 
exists for couples availing of CBRC. Any decision to proceed with therapy is based 
upon a good understanding of procedures, risks and potential complications. While 
ART services routinely present extensive or less extensive medical information to 
their patients, if a language barrier exists it is possible that couples might not be 
making an informed choice prior to pursuing treatment. 
From a medical perspective, patients must be aware that the likelihood of 
receiving safe treatment and conceiving varies according to many aspects of care. 
Furthermore, if medical complications have occurred, the lack of medical 
information, particularly if an acute event that precludes patient cooperation, makes 
patient management far more difficult. A non-exhaustive list of important “good 
medical practice” standards expected from ART units6 are detailed in Table 2.  
 
Table 2. Standards of care expected in all European ART units according to EU law. 
Trained and accredited medical, nursing, embryology staff 
Fully monitored laboratory equipment 
Appropriate laboratory air quality monitoring 
Quality systems 
Segregated tissue storage, fully monitored  
Written procedures followed for all cases 
Compulsory testing of donors 
Compulsory testing of surrogates 
 
From a legal perspective different countries have different stipulation in 
relation to the provision of ART and some have no ART law at all. In consequence, it 
is very unlikely that any recourse to legal support in the country of residence, in the 
circumstances of a medically culpable service abroad, will be available. 
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The country of residence 
The impact on the medical and legal system of the residence country is not 
negligible. 
Cross border reproductive care (CBRC), or the movement of patients within 
the EU member states or to neighboring non-EU countries, seeking ART treatment 
outside their country of residence has been in existence for many years now. The 
ESHRE CBRC Task Force has published Guidelines of good practice: ESHRE's 
Guide to Cross-border Reproductive Care8. 
The services in the country of origin will normally take the burden of 
complication like care for multiple pregnancies, particularly in high-risk patients, 
complications immediate after therapy (OHSS) and the ability to allocate a true legal 
status for the children born. Also, traceability remains the significant challenge where 
cross border care has been provided as many non-EU countries have no ART laws 
and no data collection on the outcomes of ART therapy. For example, the reality 
about genetic diseases and donor reproduction is that neither the donors nor the 
parents of a child can be forced to report a genetic disease. Adults that develop 
genetic diseases after donation might not want to return to the Donor Recruitment 
centre to make them aware, while the reporting of a birth of a child with a genetic 
disease can happen only if the parents inform the centre. As such, any reporting of 
genetic disease after donation is voluntary at the donor and recipient end. To 
encourage reporting, EU financial vehicles need to be put in place to cover the costs 
associated with such diagnoses, legal challenges and long term care of both the donor 
and the diagnosed child.  
As regards the ART practitioners in a country where CBRC, where does their 
responsibility start and finish?  The American Society for Reproductive Medicine 
(ASRM) guideline on Cross Border Reproductive Care9 raised a few important 
questions: What duties does the physician have to inform the patient about the 
opportunities for care and risks and benefits specific to treatments abroad? Even more 
important what duty, responsibility to care for a patient that returns to the country of 
origin, particularly in the circumstances of a poor outcome and no treatment details or 
medical records, the physician has? 
As regards Europe, it is unrealistic to expect that obstetricians working outside 
the ART units, and thus not falling under the umbrella of the EUTC Directive, will 
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report any SARE to the CA. There is no obligation upon such practitioners to report 
any events and furthermore they have a duty of patient confidentiality, which will take 
precedence. From previous experience with implementing the EUTCD this vigilance 
recommendation is unrealistic and will not easily be implemented in the EU countries. 
Ideally, a close interaction between the ART practitioner providing the treatment and 
the practitioner that does the follow up of the CBRC patient (once it returns to its 
country of origin) should be encouraged and nourished.  Only then the patient will 
have a smooth transition of care from provider to follow up physician and all adverse 
events easily identified, reported and followed up. 
The child to be 
The future child’s wellbeing and ability to know their origins, genetic or social 
as well as their upbringing is a topic that does not currently receive enough attention. 
While the issue of donor anonymity has preoccupied both patients and 
regulators for a long time, country specific legislation varies across Europe and the 
issue of pan-European identification of donors is, at least at present, utopic. 
If a patient receives treatment in an European country where the donor 
anonymity is guaranteed there is no legal obligation for the provider of the 
reproductive material sample or the treatment centre to release any donor related 
information to a third party. Specific cases, where the release of information is 
necessary in the interest of reducing future harm (i.e. transmission should be explored 
through the Competent Authorities rapid alerts systems in place in all European 
countries.  Yet, should all parents of children born from donor treatments be forced by 
law to discuss the mode of conception and the genetic origins with their child? 
What about children that have been born abroad using surrogacy and which 
have no legal rights in the country where their family resides? In the majority of 
European countries surrogacy is not practiced. Couples are forced to pursue such 
therapy abroad or indeed on a different continent. The legal paperwork on return 
home is a challenge and will expose their children to the risk of no birth certificate or 
national identity and significant inheritance challenges.  
Many centers offer the promise of “pregnancy” at your desired age” by 
promoting egg freezing, social or for donation.  The main concerns are related to poor 
patient information, false sense that pregnancy at advanced maternal age is a 
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desirable, safe and realistic family option and the ethical issue of creating 
reproductive banks for convenience only. A significant difference exist between 
freezing where a medical indication exists (family history of premature ovarian 
failure, severe medical conditions that affect ovarian function or where adjuvant 
therapy like chemo or radio therapy is required) and social freezing where an 
individuals desire to delay conception is the main reason for the intervention. Yet, it 
appears that, particularly the latter, is fast moving, away from the practice of medicine 
and into the convenience or social fad. One can envisage that children born from 
socially frozen eggs will be exposed to unnecessary risks related to pregnancy specific 
risks at advanced maternal age. Furthermore, such born children might find 
themselves orphans, before reaching maturity with all the associated social and 
psychological consequences attached to such a life-altering scenario. Last but not 
least, important issues like who owns the reproductive material, who is allowed to use 
it, can it be inherited or passed on to next generations are awaiting societal, legal and 
medical answers. Of particular concern is the potential patient exploitation through 
storage fees for a long period of time. 
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